Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis

BACKGROUND: Despite cefoxitin's in vitro resistance to hydrolysis by extended-spectrum beta-lactamases (ESBL), treatment of ESBL-producing Klebsiella pneumoniae (KP) infections with cefoxitin remains controversial. The aim of our study was to compare the clinical efficacy of cefoxitin as defini...

Descripción completa

Detalles Bibliográficos
Autores principales: Dequidt, Tanguy, Bastian, Sylvaine, Nacher, Mathieu, Breurec, Sébastien, Carles, Michel, Thiery, Guillaume, Camous, Laurent, Tressieres, Benoit, Valette, Marc, Pommier, Jean-David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619259/
https://www.ncbi.nlm.nih.gov/pubmed/37915017
http://dx.doi.org/10.1186/s13054-023-04712-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619259/
https://www.ncbi.nlm.nih.gov/pubmed/37915017
http://dx.doi.org/10.1186/s13054-023-04712-2

Ejemplares similares